High concordance between two companion diagnostics tests: a concordance study between the HercepTest and the HER2 FISH pharmDx kit.

The present study was done to investigate the concordance between the HER2 status measured by immunohistochemical analysis (HercepTest, DAKO, Carpinteria, CA) and fluorescence in situ hybridization (FISH; HER2 FISH pharmDx, DAKO) in a large study cohort (n = 681) of patients with high-risk breast cancer. A high agreement between immunohistochemical and FISH results was demonstrated. For the whole study population, the agreement between the 2 assays was 93.1% with a corresponding κ coefficient of 0.85. When the equivocal immunohistochemical 2+ cases were excluded from the analysis (n = 79), the agreement increased to 95.0% with a κ coefficient of 0.90. When the cutoff value for amplified/nonamplified cases in the HER2 FISH assay was increased from 2.0 to 2.2 as recommended in the American Society of Clinical Oncology/College of American Pathologists guidelines, the concordance between the 2 assays was 94.3% with a κ coefficient of 0.87 in the whole study population. When the equivocal immunohistochemical 2+ cases were excluded from this analysis, the concordance is similar (95.7% with a κ coefficient of 0.91).

[1]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[2]  J. T. Jørgensen.  Targeted HER2 Treatment in Advanced Gastric Cancer , 2010, Oncology.

[3]  S. Franco,et al.  Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer , 2010, The oncologist.

[4]  U. Scherf,et al.  Approval of novel biomarkers: FDA's perspective and major requests , 2010, Scandinavian journal of clinical and laboratory investigation. Supplementum.

[5]  W. Sui,et al.  Comparison of immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) assessment for Her-2 status in breast cancer , 2009, World journal of surgical oncology.

[6]  E. Perez,et al.  Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. , 2009, The oncologist.

[7]  N. Sneige,et al.  Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases. , 2009, Archives of pathology & laboratory medicine.

[8]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[9]  K. Gelmon,et al.  Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. , 2008, Archives of pathology & laboratory medicine.

[10]  H. Gómez,et al.  Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Plastiras,et al.  Comparison of Chromogenic In Situ Hybridisation with Fluorescence In Situ Hybridisation and Immunohistochemistry for the Assessment of Her-2/neu Oncogene in Archival Material of Breast Carcinoma , 2008, Acta histochemica et cytochemica.

[12]  H. Mouridsen,et al.  The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D , 2008, Acta oncologica.

[13]  K. Nielsen,et al.  Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer. , 2007, The oncologist.

[14]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[15]  Helena R. Chang,et al.  Histopathologic Characteristics Predicting HER‐2/neu Amplification in Breast Cancer , 2005, The breast journal.

[16]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[17]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[18]  M. Press,et al.  Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab , 2005, Breast Cancer Research and Treatment.

[19]  D. Snover,et al.  Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. , 2005, American journal of clinical pathology.

[20]  N. Weidner,et al.  Her2 Amplification: Correlation of Chromogenic In Situ Hybridization With Immunohistochemistry and Fluorescence In Situ Hybridization , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[21]  N. Dandachi,et al.  Comparison of chromogenic in situ hybridization with other methodologies for HER2 status assesment in breast cancer , 2004, Journal of Molecular Histology.

[22]  M. Ladanyi,et al.  HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2,279 cases and comparison of dual-color and single-color scoring. , 2004, American journal of clinical pathology.

[23]  L. Goldstein,et al.  HER-2 testing in breast cancer using parallel tissue-based methods. , 2004, JAMA.

[24]  E. Balslev,et al.  Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes , 2004, Acta oncologica.

[25]  C. Cohen,et al.  Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. , 2003, Human pathology.

[26]  M. Ladanyi,et al.  Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. , 2003, The Journal of molecular diagnostics : JMD.

[27]  J. Beneke,et al.  HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. , 2002, American journal of clinical pathology.

[28]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[29]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[30]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[31]  J. R. Landis,et al.  The measurement of observer agreement for categorical data. , 1977, Biometrics.

[32]  F. Hamdy,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.

[33]  E. Slodkowska,et al.  Comparison of Quantitative Immunofluorescence With Conventional Methods for HER2/neu Testing With Respect to Response to Trastuzumab Therapy in Metastatic Breast Cancer , 2009 .

[34]  Y. Oda,et al.  Protein overexpression and gene amplification of c-erbB-2 in breast carcinomas: a comparative study of immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissues. , 2002, Human pathology.